Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer

References

• National Cancer Institute Surveillance, Epidemiology, and End Results Program [webpage on the Internet]Cancer Stat Facts: Female Breast Cancer2018 Available from: https://seer.cancer.gov/statfacts/html/breast.htmlAccessed July 12, 2018
   Google Scholar
• BlowsFMDriverKESchmidtMKSubtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studiesPLoS Med201075e10027920520800
   PubMed Web of Science ®Google Scholar
• RugoHSRumbleRBMacraeEEndocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology GuidelineJ Clin Oncol201634253069310327217461
   PubMed Web of Science ®Google Scholar
• PartridgeAHRumbleRBCareyLAChemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice GuidelineJ Clin Oncol201432293307332925185096
   PubMed Web of Science ®Google Scholar
• ReinertTDebiasiMBinesJBarriosCHTrends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancerBreast Cancer Res Treat2018168245746529190006
   PubMed Web of Science ®Google Scholar
• FinnRSCrownJPLangIThe cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyLancet Oncol2015161253525524798
   PubMed Web of Science ®Google Scholar
• FinnRSMartinMRugoHSPalbociclib and letrozole in advanced breast cancerN Engl J Med2016375201925193627959613
   PubMed Web of Science ®Google Scholar
• GoetzMPToiMCamponeMMONARCH 3: Abemaci-clib as initial therapy for advanced breast cancerJ Clin Oncol201735323638364628968163
   PubMed Web of Science ®Google Scholar
• HortobagyiGNStemmerSMBurrisHAUpdated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerAnn Oncol20182971541154729718092
   PubMed Web of Science ®Google Scholar
• TripathyDImSAColleoniMRibociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialLancet Oncol201819790491529804902
   PubMed Web of Science ®Google Scholar
• Kisqali [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2018
   Google Scholar
• Ibrance [package insert]New York, NYPfizer2018
   Google Scholar
• BeaverJAAmiri-KordestaniLCharlabRFDA Approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancerClin Cancer Res201521214760476626324739
   PubMed Web of Science ®Google Scholar
• BursteinHJMayerELDeMicheleATreatment patterns for young women with HR+/HER2− metastatic breast cancer in the United States in the era of CDK 4/6 inhibitorsSan Antonio Breast Cancer SymposiumDecember 5–9, 2017San Antonio, TX
   Google Scholar
• ZanottiGHungerMPerkinsJJHorblyukRMartinMTreatment patterns and real world clinical outcomes in ER+/HER2− post-menopausal metastatic breast cancer patients in the United StatesBMC Cancer201717139328578656
   PubMedGoogle Scholar
• HortobagyiGNStemmerSMBurrisHARibociclib as first-line therapy for HR-positive, advanced breast cancerN Engl J Med2016375181738174827717303
   PubMed Web of Science ®Google Scholar
• RugoHSFinnRSDierasVPalbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: efficacy and safety updates with longer follow-up across patient subgroupsSan Antonio Breast Cancer SymposiumDecember 5–7, 2017San Antonio, TX
   Google Scholar
• RugoHSTurnerNCFinnRSPalbociclib plus endocrine therapy in older women with HR+/HER2− advanced breast cancer: a pooled analysis of randomised PALOMA clinical studiesEur J Cancer201810112313330053671
   PubMed Web of Science ®Google Scholar
• SonkeGSHartLLCamponeMRibociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trialBreast Cancer Res Treat2018167365966929058175
   PubMed Web of Science ®Google Scholar
• SinghHHowieLBloomquistEU.S. Food and Drug Administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapySan Antonio Breast Cancer SymposiumDecember 5–9, 2017San Antonio, TX
   Google Scholar
• LeeSJParkSAhnHKImplications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancerCancer Res Treat2011432899521811424
   PubMed Web of Science ®Google Scholar
• SchröderJFietzTKöhlerATreatment and pattern of bone metastases in 1094 patients with advanced breast cancer - results from the prospective German Tumour Registry Breast Cancer cohort studyEur J Cancer20177913914828494404
   PubMed Web of Science ®Google Scholar
• SledgeGWToiMNevenPMONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapyJ Clin Oncol201735252875288428580882
   PubMed Web of Science ®Google Scholar
• TurnerNCFinnRSMartinMClinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastasesAnn Oncol201829366968029342248
   PubMed Web of Science ®Google Scholar
• GoetzMPO’ShaughnessyJSledgeGWThe benefit of abemaciclib in prognostic subgroups: an exploratory analysis of combined data from the MONARCH 2 and 3 studiesSan Antonio Breast Cancer SymposiumDecember 5–9, 2017San Antonio, TX
   Google Scholar
• BurrisHAChanACamponeMFirst-line ribociclib + letrozole in patients with HR+, HER2− advanced breast cancer presenting with visceral metastases or bone-only disease: a subgroup analysis of the MONALEESA-2 trialSan Antonio Breast Cancer SymposiumDecember 6–10, 2016San Antonio, TX
   Google Scholar
• FinnRSDierasVRugoHSPalbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: efficacy and safety across patient subgroupsAmerican Society of Clinical Oncology Annual MeetingJune 2–6, 2017Chicago, IL
   Google Scholar
• JanniWAlbaEBachelotTFirst-line ribociclib plus letrozole in postmenopausal women with HR+, HER2− advanced breast cancer: tumor response and pain reduction in the phase 3 MONALEESA-2 trialBreast Cancer Res Treat2018169346947929404806
   PubMed Web of Science ®Google Scholar
• TripathyDSohnJImS-AFirst-line ribociclib or placebo combined with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the randomized Phase III MONALEESA-7 trialSan Antonio Breast Cancer SymposiumDecember 5–9, 2017San Antonio, TX
   Google Scholar
• GradisharWJKrasnojonDCheporovSSignificantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancerJ Clin Oncol200927223611361919470941
   PubMed Web of Science ®Google Scholar
• KatsumataNWatanabeTMinamiHPhase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)Ann Oncol20092071210121519254942
   PubMed Web of Science ®Google Scholar
• NabholtzJMGelmonKBontenbalMMulticenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancerJ Clin Oncol1996146185818678656254
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJMilesDVukeljaSSuperior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial resultsJ Clin Oncol200220122812282312065558
   PubMed Web of Science ®Google Scholar
• RoccaASchironeAMaltoniRProgress with palbociclib in breast cancer: latest evidence and clinical considerationsTher Adv Med Oncol2017928310528203301
   PubMed Web of Science ®Google Scholar
• RobertsonJFRDi LeoAFazalMLichfieldJEllisMJFulvestrant for hormone receptor-positive advanced breast cancer in patients with visceral versus non-visceral metastases: findings from FALCON, FIRST, AND CONFIRMSan Antonio Breast Cancer SymposiumDecember 5–9, 2017San Antonio, TX
   Google Scholar
• SammonsSLToppingDLBlackwellKLHR+, HER2− advanced breast cancer and CDK4/6 inhibitors: mode of action, clinical activity, and safety profilesCurr Cancer Drug Targets201717763764928359238
   PubMed Web of Science ®Google Scholar
• SmithTJBohlkeKLymanGHRecommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201533283199321226169616
   PubMed Web of Science ®Google Scholar
• DierasVHarbeckNJoyAAPALOMA-2: Neutropenia patterns in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative first-line advanced breast cancer receiving palbociclib plus letrozoleEuropean Society for Medical Oncology CongressSeptember 8–12, 2017Madrid, Spain
   Google Scholar
• JanniWBurrisHABlackwellKLFirst-line ribociclib + letrozole for postmenopausal women with HR+, HER2− ABC: MONALEESA-2 safety resultsAmerican Society of Clinical Oncology Annual MeetingJune 2–6, 2017Chicago, IL
   Google Scholar
• FinnRSCrownJPEttlJEfficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18Breast Cancer Res20161816727349747
   PubMed Web of Science ®Google Scholar
• Verzenio [package insert]Indianapolis, INEli Lilly and Company2018
   Google Scholar
• U.S. Department of Health and Human ServicesCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdfAccessed March 6, 2018
   Google Scholar
• VandenberkBVandaelERobynsTWhich QT correction formulae to use for QT monitoring?J Am Heart Assoc201656e00326427317349
   PubMed Web of Science ®Google Scholar
• DrewBJAckermanMJFunkMPrevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology FoundationJ Am Coll Cardiol201055993494720185054
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govA study of palbociclib (PD-0332991) + letrozole vs. letrozole for 1st line treatment of postmenopausal women with ER+/HER2− advanced breast cancer (PALOMA-2) Available from: https://www.clinicaltrials.gov/ct2/show/results/NCT01740427. NLM identifier: NCT01740427Accessed January 18, 2017
   Google Scholar
• RugoHSDiérasVGelmonKAImpact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trialAnn Oncol201829488889429360932
   PubMed Web of Science ®Google Scholar
• BellTCrownJPLangIImpact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatmentCurr Med Res Opin201632595996526894413
   PubMed Web of Science ®Google Scholar
• VermaSO’ShaughnessyJBurrisHAHealth-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2Breast Cancer Res Treat2018170353554529654415
   PubMed Web of Science ®Google Scholar
• GoodRx.com [database on the Internet]Palbociclib (Ibrance) Available from: https://www.goodrx.com/palbociclibAccessed August 23, 2018
   Google Scholar
• GoodRx.com [database on the Internet]Ribociclib (Kisqali) Available from: https://www.goodrx.com/ribociclibAccessed August 23, 2018
   Google Scholar
• GoodRx.com [database on the Internet]Abemaciclib (Verzenio) Available from: https://www.goodrx.com/abemaciclibAccessed August 23, 2018
   Google Scholar
• MamiyaHTaharaRKTolaneySMChoudhryNKNajafzadehMCost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancerAnn Oncol20172881825183128472324
   PubMed Web of Science ®Google Scholar
• MustacchiGGeneraliDCost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugsJ Med Econ201720440540828105869
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals CorporationFinancial Resources Available from: https://www.us.kisqali.com/metastatic-breast-cancer/patient-support/financial-resources/Accessed August 23, 2018
   Google Scholar
• Pfizer Corporation [database on the Internet]Financial Assistance Available from: https://www.ibrance.com/financial-assistanceAccessed August 23, 2018
   Google Scholar
• Eli Lilly and CompanySavings Support [database on the Internet] Available from: https://www.verzenio.com/savings-supportAccessed August 23, 2018
   Google Scholar
• Herrera-AbreuMTPalafoxMAsgharUEarly adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancerCancer Res20167682301231327020857
   PubMed Web of Science ®Google Scholar
• KnudsenESWitkiewiczAKThe strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategiesTrends Cancer201731395528303264
   PubMed Web of Science ®Google Scholar
• LenihanCBouchekioua-BouzaghouKAbdulghaniRChupinJShiaASchmid CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapySan Antonio Breast Cancer SymposiumDecember 6–10, 2016San Antonio, TX
   Google Scholar
• XiaoYOngCCDaemenAFriedmanLO’BrienTIdentification of preclinical mechanisms driving acquired resistance to selective ERa degraders (SERDs), CDK4/6 inhibitors, or to combinations of both agentsSan Antonio Breast Cancer SymposiumDecember 6–10, 2016San Antonio, TX
   Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• FinnRJiangYRugoHBiomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER+/HER2-advanced breast cancer (ABC)European Society for Medical Oncology CongressOctober 7–11, 2016Copenhagen, Denmark
   Google Scholar
• HortobagyiGNStemmerSMCamponeMFirst-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: efficacy by baseline circulating tumor DNA alterations in MONALEESA-2San Antonio Breast Cancer SymposiumDecember 5–9, 2017San Antonio, TX
   Google Scholar
• AndreFStemmerSMCamponeMRibociclib + letrozole for first-line treatment of HR+, HER2− advanced breast cancer: efficacy by baseline tumor markersAmerican Association for Cancer Research Annual MeetingApril 1–5, 2017Washington, DC
   Google Scholar
• FinnRSLiuYMartinMComprehensive gene expression biomarker analysis of cyclin-dependent kinases 4/6 and endocrine pathways from the PALOMA-2 studySan Antonio Breast Cancer SymposiumDecember 5–9, 2017San Antonio, TX
   Google Scholar
• DemicheleAClarkASTanKSCDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessmentClin Cancer Res2015215995100125501126
   PubMed Web of Science ®Google Scholar
• CruzMRSBehdadAStricklandKPatterns of genomic alterations in ER-positive advanced breast cancer patients treated with CDK4/6 inhibitorsSan Antonio Breast Cancer SymposiumDecember 5–9, 2017San Antonio, TX
   Google Scholar
• PatnaikARosenLSTolaneySMEfficacy and safety of abemaci-clib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumorsCancer Discov20166774075327217383
   PubMed Web of Science ®Google Scholar
• MalorniLCuriglianoGMinisiniAA phase II trial of the CDK4/6 inhibitor Palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2−) metastatic breast cancer (mBC) (TREnd trial)American Society of Clinical Oncology Annual MeetingJune 2–6, 2017Chicago, IL
   Google Scholar
• MalorniLCuriglianoGMinisiniAMPalbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trialAnn Oncol20182981748175429893790
   PubMed Web of Science ®Google Scholar
• MoulderSKaruturiMYardleyDARibociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: efficacy and safety results from Phase 2 of the TRINITI-1 studyAmerican Association for Cancer ResearchApril 14–18, 2018Chicago, IL
   Google Scholar
• ClinicalTrials.govMolecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC (BioPER) Available from: https://www.clinicaltrials.gov/ct2/show/NCT03184090. NLM identifier: NCT03184090Accessed August 24, 2018
   Google Scholar
• BlackwellKLPaluch-ShimonSCamponeMSubsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib + letrozole vs placebo + letrozole in the Phase III MONALEESA-2 studySan Antonio Breast Cancer SymposiumDecember 5–9, 2017San Antonio, TX
   Google Scholar